Skip to main content
Journal of Inflammation Research logoLink to Journal of Inflammation Research
. 2026 Nov 2;19:648890. doi: 10.2147/JIR.S648890

Bioactive Compounds from Traditional Chinese Medicine for Rheumatoid Arthritis: Exposure–Response Constraints, Causal Mechanisms, and Translational Evidence

Hui Li 1, Xingwen Xie 1,2,✉, Ning Li 1,2
PMCID: PMC13742001  PMID: 42997439

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease sustained by synovial immune–stromal circuits and progressive osteoclast-mediated structural damage. This critical narrative review evaluates 15 chemically defined TCM-derived constituents selected because they have recurrent RA-relevant pharmacology together with sufficient mechanistic, exposure, safety, or translational evidence for comparative appraisal. English-language PubMed and Web of Science searches (January 2010–31 July 2026, with earlier landmark studies) were used; preclinical evidence was assessed separately from human evidence. Across the literature, reported effects converge on macrophages, RA fibroblast-like synoviocytes (RA-FLSs), T-cell programs, osteoclastogenesis, neutrophil extracellular trap (NET) formation, and recurrent signaling nodes including NF-κB/MAPK, JAK/STAT, PI3K–AKT–mTOR, ROS–Nrf2, NLRP3–caspase-1, RANKL–NFATc1, and HIF-1α–VEGF. However, most isolated compounds remain supported mainly by cell and animal studies, and downstream pathway changes often provide associative rather than causal mechanistic evidence. The strongest human signal concerns standardized Tripterygium wilfordii Hook F (TwHF) products, which must not be equated with isolated triptolide or celastrol. Small trials of formulation-specific curcumin and clinical use of sinomenine provide additional but less definitive signals. Translation is constrained by low or formulation-dependent exposure, active metabolites, product–constituent non-equivalence, toxicity, and limited target-engagement or rescue data. TCM-derived constituents should therefore be viewed as mechanistic leads or potential adjuncts rather than substitutes for guideline-directed DMARD therapy. The most credible development paths are standardized clinically studied botanical products, gut-restricted exposure-aware strategies such as berberine, and chemically defined leads with demonstrated target engagement, clinically achievable exposure, structural benefit, and combination safety.

Keywords: rheumatoid arthritis, traditional Chinese medicine, bioactive constituent, synovial immunology, fibroblast-like synoviocyte, macrophage, osteoclast, inflammasome

Introduction

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by symmetric inflammatory polyarthritis, synovial hyperplasia, cartilage loss, focal bone erosion, and variable extra-articular involvement. Global analyses indicate that RA remains a growing cause of disability, with prevalence increasing as populations age and survive longer with chronic disease.1 The biological problem is not simply excess inflammation. RA develops through a sequence that includes loss of tolerance to post-translationally modified proteins, autoantibody maturation, mucosal and systemic immune activation, recruitment of leukocytes into the synovium, and establishment of a self-sustaining immune-stromal niche.2–5 Once this niche is established, synovial macrophages, T and B lymphocytes, neutrophils, endothelial cells, osteoclast-lineage cells, and fibroblast-like synoviocytes (FLSs) exchange cytokines, chemokines, growth factors, metabolites, extracellular vesicles, and matrix-derived danger signals. The result is a tissue-level circuit that can persist even when one inflammatory mediator is therapeutically blocked.6–8

Disease-modifying antirheumatic drugs (DMARDs) remain the standard of care, and contemporary RA management is based on treat-to-target principles with methotrexate as a common anchor drug and escalation to biologic or targeted synthetic DMARDs when required.9,10 These therapies have substantially improved remission and structural outcomes, but primary non-response, secondary loss of response, intolerance, infection risk, organ toxicity, reproductive considerations, cardiovascular risk signals for selected agents, and disparities in access continue to motivate adjunctive pharmacological research. Any TCM-derived intervention must therefore be evaluated against modern treat-to-target care, including methotrexate (MTX), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs), rather than against untreated disease.

Traditional Chinese medicine (TCM) has been used for inflammatory arthritides through botanical extracts, multi-herb formulations, and purified or semi-purified constituents. Modern pharmacology has identified structurally diverse molecules with anti-inflammatory or immunoregulatory actions, including triptolide and celastrol from Tripterygium wilfordii, sinomenine from Sinomenium acutum, berberine from Coptis species and related botanicals, paeoniflorin from Paeonia lactiflora, tanshinone IIA from Salvia miltiorrhiza, and icariin from Epimedium species. The term “TCM-derived” describes the historical or pharmacognostic source, not chemical exclusivity: curcumin, quercetin, resveratrol, and several other compounds occur broadly in plants and foods. This distinction matters because traditional use, botanical extraction, isolated-compound pharmacology, and clinical efficacy are different levels of evidence.11,12

Recent reviews have comprehensively catalogued plant-derived compounds, extracts, inflammatory pathways, and pharmacokinetic limitations in RA and arthritis.13,14 The present review asks a narrower and more translational question. Rather than treating pathway breadth as mechanistic proof, we appraise whether a chemically defined intervention reaches a relevant compartment at a plausible exposure, whether a proximal target or causal pathway has been demonstrated, whether the model represents established disease, whether safety permits chronic use, and whether the clinical intervention is actually the same product as the preclinical molecule. The review therefore integrates five evidence dimensions—chemical identity, model relevance, exposure, proximal mechanism, and replication—and explicitly separates standardized botanical products from isolated constituents and metabolites. Table 1 summarizes this evidence hierarchy, whereas Table 2 focuses on exposure, formulation, and human translation. Figure 1 provides an evidence-aware mechanistic overview. This exposure-aware, causal-mechanistic framework is the principal distinction from recent compound-by-pathway inventories.

Table 1.

Evidence Hierarchy for 15 Representative TCM-Derived Constituents in Rheumatoid Arthritis

Constituent Chemical Class/Intervention Type Representative RA Systems Route/Exposure Context Proximal Target Evidence Key Limitation/Toxicity Flag Highest Evidence Tier
Triptolide Diterpene triepoxide; isolated molecule RA-FLSs; CIA/AIA; chronic arthritis Cell/animal studies; systemic exposure constrained by narrow therapeutic window Mainly downstream/associative; direct causal target engagement in RA not established Reproductive, hepatic, renal, hematologic and immune toxicity; TwHF product efficacy is not attributable to triptolide alone Animal therapeutic/human evidence applies to TwHF product, not isolated triptolide
Celastrol Quinone-methide triterpenoid; isolated molecule Macrophage-like systems; AIA/CFA; FLS/osteoclast studies Predominantly preclinical; formulation-dependent exposure Electrophilic covalent reactivity supports plausible proximal chemistry, but RA-selective target engagement remains incomplete Promiscuous thiol reactivity and narrow safety window Animal therapeutic
Sinomenine Morphinan alkaloid; molecule distinct from marketed hydrochloride product RA-FLSs; AIA; neutrophil studies; human biomarker/clinical reports Oral/clinical product use; exposure–response incompletely defined TLR4–MyD88–NF-κB and NET findings mainly associative Product–molecule non-equivalence; target identity not established Human clinical/biomarker
Berberine Isoquinoline alkaloid; isolated molecule CIA; gut microbiota models; T-cell assays Oral parent drug: low systemic but high intestinal exposure Gut cortistatin/microbiota model is exposure-coherent; direct joint targets not established Poor systemic bioavailability; metabolite/microbiota dependence Animal therapeutic
Paeoniflorin Monoterpene glycoside; isolated molecule distinct from total glucosides of peony AIA/CIA; RA-FLSs Predominantly oral preclinical; extensive metabolism TLR4/circRNA claims mainly associative Limited human PK/PD and target engagement; product–constituent distinction Animal therapeutic
Curcumin Diarylheptanoid polyphenol; multiple non-equivalent formulations RA-FLSs; CIA/AIA; small RCTs Oral exposure highly formulation dependent; free parent usually low Downstream NF-κB/Nrf2 and related readouts mostly associative Formulation heterogeneity; low/variable bioavailability Small RCTs
Artesunate Semi-synthetic artemisinin derivative RA-FLSs; CIA; osteoclast/bone models Preclinical systemic dosing; anti-RA clinical exposure undefined NF-κB/PI3K–AKT/p62–Nrf2 findings mainly associative Long-term RA dosing and safety not established Animal therapeutic
Baicalein Flavone; isolated molecule RA-FLSs; experimental arthritis Preclinical cell/animal exposure PI3K–AKT–mTOR changes mainly associative Active conjugates and achievable joint exposure uncertain Animal/cell
Quercetin Flavonol; broadly distributed phytochemical RA-FLSs; Th17; osteoclast assays; CIA Variable oral exposure; extensive metabolism Integrated Th17–FLS–RANKL/osteoclast evidence, but proximal target unresolved Non-TCM specificity; low/variable parent exposure Animal therapeutic
Icariin Prenylated flavonol glycoside CIA/AIA; macrophage/synoviocyte assays Preclinical oral/systemic exposure; active metabolites likely relevant miR-223-3p/NLRP3 and ferroptosis readouts mostly associative Ferroptosis claims require rescue; human target engagement absent Animal therapeutic
Tanshinone IIA Abietane diterpenoid quinone RA-FLSs; osteoclast cultures; CIA Preclinical; formulation-dependent exposure LDHC–ROS and apoptosis studies suggest proximal hypotheses but require replication Limited human RA evidence Animal therapeutic
Ginsenosides Triterpenoid saponins/metabolites; constituent class AIA/CIA; immune-cell assays Parent saponins undergo extensive metabolism, including compound K formation PPARγ/NF-κB/STAT3/Th17-Treg signals mainly associative Different ginsenosides/metabolites are not interchangeable Animal therapeutic
Andrographolide Labdane diterpenoid lactone RA-FLSs; CIA Preclinical systemic exposure Electrophilic chemistry plausible; HIF-1α/NF-κB effects mainly downstream Target selectivity and chronic exposure unclear Animal therapeutic
Emodin Anthraquinone Neutrophil/macrophage–FLS systems; arthritis models Preclinical; systemic exposure and metabolites variable NET formation/apoptosis findings need cytotoxicity controls Gastrointestinal/hepatic safety; PK uncertainty Animal/cell
Norisoboldine Aporphine alkaloid Osteoclast cultures; CIA Preclinical RANKL-driven osteoclast inhibition; proximal target incomplete Limited human data Animal therapeutic

Notes: Evidence tiers identify the highest level of evidence for the specific intervention named in the first column. “Associative” indicates that downstream pathway changes were reported without sufficient target-engagement, necessity, or rescue evidence. Standardized products, purified constituents, metabolites, and formulation-enhanced preparations are treated as distinct interventions.

Abbreviations: RA-FLSs, rheumatoid arthritis fibroblast-like synoviocytes; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; PK/PD, pharmacokinetics/pharmacodynamics; RCT, randomized controlled trial.

Table 2.

Translational PK/PD and Clinical-Product Considerations for the Best-Studied Interventions

Intervention Clinical/Product Identity Representative Human Regimen/Evidence Exposure/PK Issue Structural Outcome Evidence Key Safety/Interpretive Issue
Standardized TwHF product Botanical extract/glycoside product; not isolated triptolide/celastrol TRIFRA: 207 patients; TwHF 20 mg three times daily, MTX 12.5 mg weekly, or combination for 24 weeks;15 2023 consensus synthesized 19 RCTs/1795 participants16 Product composition and batch standardization determine exposure; constituent attribution is invalid without compositional PK Clinical disease-activity benefit shown; robust long-term radiographic/structural evidence remains limited Reproductive toxicity, hepatic/renal risk, hematologic and GI adverse effects; caution in pregnancy/gestation planning
Sinomenine/sinomenine hydrochloride Purified alkaloid versus marketed hydrochloride product Clinical and meta-analytic signals exist,17,18 but trial quality, formulation and background therapy vary Human exposure–response and proximal target engagement remain incompletely defined Structural protection not established to modern DMARD standards Product–molecule non-equivalence; combination safety requires prospective study
Curcumin formulations Conventional curcumin, nanomicelles, and bioavailability-enhanced matrices are pharmacokinetically distinct Examples include 36-patient placebo-controlled trial of 250 or 500 mg twice daily for 90 days19 and other small formulation-specific trials20–23 Free parent exposure is low and strongly formulation dependent; conjugates/metabolites may dominate24–27 No convincing evidence of prevention of radiographic progression Small samples, heterogeneous formulations/background DMARDs; do not pool conceptually as one “curcumin” intervention
Berberine Isolated alkaloid; oral parent drug Human RA efficacy evidence limited relative to preclinical literature Extensive intestinal first-pass elimination; low plasma parent concentration with high gut exposure28 No established human structural benefit Direct synovial mechanism may be implausible after oral dosing; gut-restricted mechanism is more exposure-consistent
Paeoniflorin/total glucosides of peony Isolated glycoside versus standardized multicomponent product Clinical product evidence should not be assigned automatically to paeoniflorin Extensive metabolism; limited human synovial exposure data Not established for isolated paeoniflorin Product–constituent confusion and weak target engagement
Triptolide/celastrol Purified TwHF constituents No evidence equivalent to standardized TwHF RCTs Exposure constrained by toxicity; formulation and tissue distribution remain important Preclinical structural/inflammatory signals only Narrow therapeutic window; cannot inherit clinical efficacy claims from TwHF extract

Notes: Human regimens are included only when directly supported by cited clinical sources. Absence of a value indicates that clinically interpretable exposure or structural evidence is not established; no unverified concentration has been imputed.

Figure 1.

A four-column infographic linking TCM constituents to molecular nodes, immune remodeling and disease effects. Four-column infographic summarizing links from representative constituents to molecular nodes, immune stromal remodeling and disease level effects in rheumatoid arthritis. 1 Representative constituents. Terpenoids slash diterpenoids: triptolide, celastrol, tanshinone IIA, artesunate. Alkaloids: sinomenine, berberine, norisoboldine. Polyphenols slash flavonoids: curcumin, quercetin, baicalein. Glycosides slash saponins: paeoniflorin, icariin, ginsenosides. 2 Convergent molecular nodes. NF-kappaB slash MAPK. JAK slash STAT. PI3K-AKT-mTOR. ROS-Nrf2. NLRP3-caspase-1. RANKL-NFATc1. HIF-1alpha-VEGF. gut microbiota slash metabolites. 3 Immune-stromal remodeling. Macrophages slash monocytes: down arrow inflammatory states; up arrow pro-resolving programs; down arrow TNF, IL-1beta, IL-6 and GM-CSF. T- and B-cell responses: down arrow Th17 slash Tfh and IL-17; up arrow Treg; limited direct evidence for autoantibody suppression. Fibroblast-like synoviocytes: down arrow proliferation, migration, invasion, MMPs and RANKL; up arrow apoptosis or return toward quiescence. Osteoclast lineage: down arrow RANKL signaling, differentiation and resorption. Neutrophils, DCs and endothelium: down arrow NETs, costimulation and angiogenesis left parenthesis emerging or compound-specific evidence right parenthesis. Stress and cell-death programs: down arrow ROS, pyroptosis and ferroptosis; restored autophagy and mitochondrial quality. 4 Disease-level effects. Reduced synovitis and pannus. Preserved cartilage and matrix. Reduced focal bone erosion. Improved pain, mobility and physical function. Arrows connect the four columns from left to right. Evidence hierarchy: isolated-cell assays less than animal arthritis models less than human tissue validation less than randomized clinical evidence. Most mechanisms remain preclinical and require exposure-target engagement confirmation. TCM, traditional Chinese medicine; FLS, fibroblast-like synoviocyte; NET, neutrophil extracellular trap; DC, dendritic cell; MMP, matrix metalloproteinase.

Integrated immunological mechanisms of TCM-derived bioactive constituents in rheumatoid arthritis. Key signaling nodes to which representative compounds converge are inflammatory, stress-response, osteoclastogenic, and angiogenic. The cellular effects include macrophages, adaptive lymphocytes, fibroblast-like synoviocytes, osteoclasts, neutrophils, dendritic cells and endothelial cells. Arrows show the proposed directionality of the relationship, NOT the strength of the causal evidence. The majority of links are based mainly on isolated-cell assays or on models of arthritis in animals; human synovial validation and randomized clinical evidence are considerably less. The arrows indicate the sequential progression from representative TCM-derived bioactive constituents to convergent molecular targets, subsequent immune–stromal remodeling, and ultimately disease-level effects. The symbols “↓” and “↑” indicate decreased/inhibited and increased/enhanced effects, respectively.

Abbreviations: DC, dendritic cell; FLS, fibroblast-like synoviocyte; MMP, matrix metalloproteinase; NET, neutrophil extracellular trap; TCM, traditional Chinese medicine.

Literature-Search Framework and Evidence Appraisal

This article is a critical narrative review, not a systematic review or meta-analysis. We searched PubMed and Web of Science for English-language publications from 1 January 2010 through 31 July 2026 and also retained earlier landmark studies when they were required to interpret clinical products, pharmacokinetics, or canonical mechanisms. The search combined RA terms with TCM/natural-product terms and compound-specific terms. A representative Boolean strategy was: (“rheumatoid arthritis” OR synovitis OR “fibroblast-like synoviocyte” OR osteoclast OR macrophage OR Th17 OR Treg OR “neutrophil extracellular trap”) AND (“traditional Chinese medicine” OR phytochemical OR “natural product” OR “bioactive constituent” OR the individual compound name) AND (mechanism OR pharmacokinetic* OR exposure OR safety OR clinical OR trial). Searches for translational evidence additionally combined each compound/product with (“target engagement” OR CETSA OR chemoproteomic* OR rescue OR CRISPR OR plasma OR synovial OR metabolite OR randomized). Reference lists of key reviews and included clinical studies were also examined. Records were screened by title/abstract and then by full text for relevance to RA pharmacology, exposure, safety, or clinical translation. Because the search was designed prospectively as a narrative review rather than a PRISMA workflow, an exact numerical screening yield was not prospectively recorded; we therefore do not report a reconstructed count that could imply false precision. This limitation is now stated explicitly.

The 15 core entities were selected using explicit inclusion logic. Eligible entities had to be chemically defined constituents or clearly defined constituent classes with recurrent RA-relevant evidence and sufficient information to support appraisal across at least two of the following domains: validated arthritis models or primary human RA systems; pharmacokinetic/exposure information; safety or therapeutic-window data; proximal mechanistic evidence; or human clinical/biomarker evidence. We also sought representation across major chemical classes and RA-relevant compartments rather than selecting compounds solely because they were frequently mentioned. Multi-component proprietary products and standardized botanical preparations were excluded from the 15-molecule core set and are discussed separately because product efficacy cannot be assigned to one marker constituent. Thus, Tripterygium glycosides/TwHF extracts, sinomenine hydrochloride products, and total glucosides of peony are treated as clinical products rather than as interchangeable evidence for triptolide/celastrol, sinomenine base, or paeoniflorin. Resveratrol and other broadly studied nutraceuticals were not included in the 15-entity core because the purpose was not to provide an exhaustive phytochemical catalogue. Evidence was graded qualitatively according to chemical characterization, model relevance, exposure/route, proximal target evidence, and replication. Network pharmacology, docking, bulk enrichment, isolated terminal cytokine changes, LC3-II alone, marker-only ferroptosis readouts, or M1/M2 marker shifts were not treated as causal mechanistic proof.

Immunopathological Framework of Rheumatoid Arthritis

Loss of Tolerance, Autoantibodies, and the Preclinical Phase

RA autoimmunity can precede clinical synovitis by years. In genetically susceptible individuals, mucosal and systemic exposures may promote post-translationally modified antigens and maturation of anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor.3–5 For pharmacological interpretation, the important point is that most TCM-derived compound studies begin after induction of experimental arthritis and therefore test suppression of established inflammation rather than prevention of tolerance loss. Changes in total immunoglobulin, rheumatoid factor, or anti-collagen antibodies in collagen-induced arthritis (CIA) should not be equated with correction of human ACPA fine specificity, germinal-center biology, or synovial B-cell pathotypes.29–34

Direct evidence for effects on autoreactive B-cell clones, plasmablast survival, ACPA glycosylation, germinal centers, or antigen presentation by human RA B cells remains limited. This gap should remain explicit rather than being replaced by broad claims of “immune balance”.

The Synovial Immune-Stromal Ecosystem

The pharmacologically relevant synovial compartments are inflammatory and resolving macrophage states, pathogenic RA-FLSs, T- and B-cell programs, neutrophils, endothelium, osteoclast-lineage cells, and their metabolic interactions. Human single-cell and spatial studies show that these states are heterogeneous and tissue-imprinted, making binary M1/M2 labels and acute cytokine-stimulated cultures inadequate surrogates for the full disease state.35–41

RA-FLSs are particularly important because lining and sublining populations contribute to cartilage invasion, matrix degradation, leukocyte recruitment, cytokine production, and RANKL-dependent osteoclastogenesis. A pharmacological study should therefore distinguish non-specific cytotoxicity from durable reprogramming of pathogenic fibroblast states and, where possible, use patient-derived cells, organoids, or multicellular synovial systems.42–44

Adaptive immune cells remain relevant because Th17-associated programs, T peripheral helper/T follicular helper cells, B cells, and plasma cells can reinforce myeloid and stromal activation. However, splenic Th17/Treg percentages or antibody titres in CIA do not by themselves demonstrate restoration of human immune tolerance. The pharmacologically relevant question is whether an intervention changes a disease-relevant cellular state at achievable exposure.40,45

Bone Erosion, Angiogenesis, and Immunometabolic Stress

Structural protection requires more than suppression of paw swelling. RANKL-driven osteoclastogenesis, RA-FLS-mediated cartilage invasion, and impaired bone repair are the key structural compartments. Studies claiming disease modification should therefore include direct bone/cartilage outcomes such as micro-computed tomography, histomorphometry, erosion scoring, or validated imaging, rather than relying only on inflammatory biomarkers.32,33,46

Hypoxia, glycolytic reprogramming, mitochondrial stress, ROS, inflammasome activation, angiogenesis, and autophagy intersect with these cellular compartments. They are pharmacologically relevant because HIF-1α, Nrf2, NLRP3, and PI3K–AKT–mTOR recur across compound studies, but changes in these nodes may be downstream consequences rather than direct targets. Figure 2 summarizes the RA compartments used in this review as the biological frame for evaluating compound evidence.47–49

Figure 2.

A three-section infographic outlining preclinical RA, chronic synovitis and joint damage pathways. Three-section infographic titled, Immunopathological Framework of Rheumatoid Arthritis. A) Loss of tolerance and the preclinical phase. Heading, Environmental slash mucosal risk factors. Items: Periodontal inflammation, Lung inflammation, Obesity, Smoking. Heading, Post-translational modifications of self-proteins. Items: Citrullination with label, Cit; Carbamylation with label, Carb; Acetylation with label, Ac. Heading, Antigen presentation by APCs. Labels: Self-antigen left parenthesis peptide right parenthesis; Dendritic cell left parenthesis macrophage right parenthesis; MHC II; T cell. Next labels: Expansion of autoreactive T cells; Autoreactive B cells. Heading, Autoantibody production. Items: ACPAs left parenthesis anti-citrullinated protein antibodies right parenthesis; Rheumatoid factor left parenthesis anti-Fc IgM slash IgG right parenthesis. Heading, Immune-complex formation. Bottom label, Preclinical RA. Sentence: Autoimmunity without clinical synovitis left parenthesis may precede arthritis by years right parenthesis. B) The synovial immune-stromal ecosystem. Label, Synovial lining layer. Labels: Resident FLSs left parenthesis homeostatic right parenthesis; Activated slash invasive FLSs left parenthesis pathogenic phenotype right parenthesis; Inflammatory macrophages slash monocytes. Central label: Chronic inflammation left parenthesis bidirectional crosstalk right parenthesis. Heading, Supporting immune and stromal cells. Items: Th17 T cells with IL-17 and IL-22; Tregs cells with IL-10 and TGF-beta; B cells slash plasma cells; Dendritic cells; Mast cells; Endothelial cells with Angiogenic factors. Heading, Key effector programs. Boxes: Pro-inflammatory cytokines listing TNF, IL-6, IL-1; Autoantibodies slash immune complexes; Tissue remodeling listing MMPs, RANKL. Bottom label, Chronic synovitis. Sentence: Sustained immune-stromal interactions drive persistent inflammation and joint tissue damage. C) Bone erosion, angiogenesis and immunometabolic stress. Joint label: Synovial pannus left parenthesis inflamed synovium right parenthesis. Three labeled pathways: Osteoclast activation and bone erosion with RANKL and labels, Osteoclast, Bone erosion; Angiogenesis with VEGF, FGF and label, New blood vessel formation; Immunometabolic stress listing Hypoxia left parenthesis HIF-1alpha right parenthesis, Mitochondrial dysfunction, Glycolytic switch. Bottom bar label, Sustained synovitis and tissue damage. Sentence: Bone destruction, cartilage loss and progressive joint dysfunction.

Immunopathological framework of rheumatoid arthritis. Rheumatoid arthritis (RA) has a series of steps that are working in concert: Loss of immune tolerance, chronic inflammation of the synovium and gradual destruction of the joints. (1) Preclinical phase: Genetic susceptibility and mucosal/systemic exposures, leading to post-translational protein modifications, autoreactive T- and B-cell activation, autoantibody production, immune-complex formation and early activation of osteoclasts. (2) Synovial immune–stromal ecosystem: pathogenic fibroblast-like synoviocytes and inflammatory macrophages create bi-directional signaling loops to maintain synovial heterogeneity, matrix degradation, recruitment of leukocytes, and production of cytokines. Other cells that influence lymphoid, myeloid, and fibroid pathotypes are T cells, B cells, plasma cells, dendritic cells, mast cells, and endothelial cells. (3) Structural damage: RANKL-dependent osteoclastogenesis, synovial cartilage invasion, defective bone formation, angiogenesis, hypoxia, metabolic reprograming, oxidative stress, inflammasome activation, and impaired autophagy all contribute to persist synovitis and irreversible structural damage. Arrows show a proposed biological relationship and not equal degree of causal evidence.

Abbreviations: ACPA, anti-citrullinated protein antibody; FLS, fibroblast-like synoviocyte; MMP, matrix metalloproteinase; NLRP3, NOD-, LRR- and pyrin domain-containing protein 3; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear factor-κB ligand; RF, rheumatoid factor; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor.

Mechanisms of Representative TCM-Derived Bioactive Constituents

Regulation of Monocytes and Synovial Macrophage Programs

Sinomenine has been associated with reduced TNF, IL-1β, and IL-6 production, altered circulating monocyte/macrophage subsets, inhibition of TLR4–MyD88–NF-κB signaling in RA-FLSs, and reduced NET formation in adjuvant-induced arthritis.17,50,51 These observations support activity across innate-immune compartments, but they do not identify a single proximal molecular target and should therefore be classified mainly as associative pathway evidence. Human target engagement and exposure–response relationships remain insufficiently defined.

Celastrol, a quinone-methide triterpenoid from T. wilfordii, has been reported to reduce ROS, NF-κB activation, NLRP3 inflammasome assembly, and IL-1β/IL-18 release in macrophage-like systems and experimental arthritis.52 The sequence is biologically coherent, but celastrol is electrophilic and can modify multiple protein thiols. Consequently, downstream NLRP3/NF-κB changes should not be interpreted as evidence of selective target engagement without chemoproteomic target identification, occupancy measurements, and genetic or pharmacological rescue. This chemical promiscuity may contribute to both potency and toxicity.

Oral berberine is associated with reduced Th17 responses, altered gut microbial/metabolite programs, and increased intestinal cortistatin in CIA.53 Because systemic parent-drug exposure is low whereas intestinal exposure is high, a gut-restricted or microbiota-mediated mechanism is more pharmacologically plausible than direct joint action after oral dosing. High-concentration cultured-cell studies may still be useful for hypothesis generation, but they should not be treated as exposure-matched proof of the in vivo mechanism.54

Curcumin, paeoniflorin, baicalein, tanshinone IIA, andrographolide, and ginsenosides have also been reported to reduce inflammatory cytokines or macrophage-associated histological signals in experimental arthritis. Many studies infer “M1-to-M2 polarization” from CD86/CD206, iNOS/arginase-1, or related markers. In human RA these marker sets do not define stable binary macrophage populations, so such findings are best described as marker shifts unless supported by single-cell, spatial, lineage, and functional validation.55,56

Modulation of T-Cell and B-Cell Responses

For TCM-derived compounds, a Th17/Treg rebalancing has been frequently reported. Berberine has been observed to decrease Th17 differentiation and Th17 related responses in CIA, and cortistatin derived from the gut has been suggested as a possible intermediate.53 Icariin has been shown to inhibit experimental arthritis via the miR-223-3p/NLRP3 signaling pathway57 while other preclinical studies have implicated icariin-derived compounds with general inflammatory and osteoclast pathways. Paeoniflorin and ginsenoside preparations have also been linked to modifications in Th17/Treg ratios and a decrease in IL-6/STAT3 signaling. Biologically, these observations make sense, as TGF-β and IL-2 promote regulatory phenotypes, while IL-6, IL-1β, and IL-23 promote Th17 programs, and metabolic stress promotes Th17 programs. However, splenic percentage changes do not define tolerance restoration and many studies do not differentiate between the stable regulatory T cells and the transiently activated effector cells that express regulatory markers.

Triptolide is a general immunosuppressive agent that can suppress T-cell activation, cytokine transcription and inflammatory gene expression. Its high potency is mechanistically important, but is clinically problematic because transcriptional inhibition is not limited to the pathogenic lymphocytes. Straightforward translation is complicated by reproductive, hepatic, renal, hematologic and immune toxicity. Evidence of a selective effect of celastrol or curcumin on pathogenic T peripheral helper cells, synovial tissue-resident T cells or autoreactive clones is also limited.

Evidence for B-cells is not as strong as the T-cell literature. A decrease in RF or anti-collagen antibody levels in animal models could be due to an overall dampening of inflammation, a change in antigen burden or a defect in plasma-cell responses. There are very few studies that address dynamics of germinal centers, affinity maturation, fine specificity of ACPA, Fc glycosylation, and antigen presentation by human RA B cells. Therefore, the term correction of autoimmunity should not be used unless tested upstream B-cell biology. This is an important opportunity for future research as B-cell rich synovial pathotypes may behave differently from myeloid- or fibroblast-dominant disease.

Suppression or Reprogramming of Fibroblast-Like Synoviocytes

RA-FLSs display tumor-like features, including resistance to apoptosis, enhanced migration and invasion, abnormal metabolism, and production of MMPs, RANKL, cytokines, and chemokines. Triptolide inhibits FLS proliferation and inflammatory mediator production, and it can interfere with angiogenic cascades.58 Artesunate suppresses TNF-induced NF-κB and PI3K-AKT signaling in FLSs and reduces migration and invasion in experimental systems.59,60 Andrographolide inhibits FLS migration and invasion through HIF-1α-related mechanisms.61 Baicalein induces apoptosis and suppresses proliferation and epithelial-mesenchymal-transition-like programs through PI3K-AKT-mTOR inhibition.62 Tanshinone IIA also promotes apoptosis in RA-FLSs.63

These results suggest that the FLSs can be viewed as a convergent pharmacological compartment, yet three interpretive issues arise again. First, acute cytokine stimulated FLS cultures do not mimic the stable epigenetic and positionally identities of lining and sublining fibroblasts. Second, selective inhibition of invasion or of cytokine release can be confused with cytotoxicity. Anti-proliferative, pro-apoptotic, and non-cytotoxic signaling effects need to be separated in dose response experiments, therefore. Third, changes in pathways, measured post cell death, do not necessarily constitute evidence of a proximal mechanism. To differentiate between true state reprogramming and a non-specific suppression, rescue experiments, target-depletion studies, real-time migration assays and human synovial organoids are required.

Paeoniflorin has been reported to suppress inflammatory responses in RA-FLSs through TLR4-related signaling and a circRNA–miRNA regulatory axis.64,65 Because ceRNA mechanisms are especially vulnerable to stoichiometric over-interpretation, these findings are treated here as hypothesis-generating rather than established causal mechanisms. The more clinically relevant test is whether paeoniflorin can alter patient-derived RA-FLS phenotypes at free parent/metabolite exposures achievable in plasma or synovial tissue.

Inhibition of Osteoclastogenesis and Structural Damage

Osteoclast inhibition is essential for any claim of structural protection. Quercetin reduces IL-17-stimulated RANKL production in RA-FLSs, suppresses Th17 differentiation, and inhibits osteoclast formation, providing a mechanistically integrated link between adaptive immunity, stroma, and bone.66 Norisoboldine inhibits osteoclast differentiation and ameliorates bone erosion in CIA.67 Tanshinone IIA suppresses osteoclastogenesis through an LDHC-ROS-related mechanism,68 while artesunate has been reported to preserve bone through p62-Nrf2 signaling.59 Icariin has additional activity on the miR-223-3p/NLRP3 axis and on ferroptosis-associated synoviocyte survival,57,69 but these findings should not be treated as direct evidence of erosion prevention.70

These studies are best when they include the use of tartrate-resistant acid phosphatase staining, resorption-pit assays, micro-computed tomography, histomorphometry, and molecular perturbation. Use of serum bone-turnover markers alone is not adequate. In addition, it is critical to distinguish direct effects on the osteoclast precursors from indirect effects that may occur as a result of decreased systemic inflammation or decreased FLS RANKL. Human validation should include osteoclastogenesis by patient monocytes, co-culture with RA-FLSs or B cells, and unbound concentrations achievable in the clinic.

To achieve structural benefit, there might be a need to control both osteoclasts and FLS-mediated cartilage damage. While an NFATc1 blocking compound that is too toxic for chronic use is not likely to be a disease-modifying therapy, a modest anti-osteoclast effect could be useful if safe, orally active, unidirectional, and additive to the effects of methotrexate or a biologic. The current animal studies do not include this risk-benefit/combination context.

Neutrophils, Dendritic Cells, Endothelial Cells, and Angiogenesis

Neutrophils are abundant in RA synovial fluid and can release proteases, ROS, alarmins, and NETs. NETs provide citrullinated antigens and may amplify autoantibody-driven inflammation. Triptolide suppresses neutrophil recruitment, cytokine release, and inflammatory activity in chronic arthritis.71 Sinomenine and emodin have also been reported to reduce NET formation or promote resolution-associated neutrophil apoptosis.51,72 These findings are relevant, but NET assays require methodological care: extracellular DNA, citrullinated histone staining, and myeloperoxidase-DNA complexes can reflect different forms of cell death. Demonstrating PAD4 dependence and excluding cytotoxic lysis would strengthen mechanistic claims.73,74

There is relatively little information on dendritic-cell research. While there are a number of constituents that in vitro decrease maturation markers or antigen-presenting capacity, few directly investigate presentation of RA-relevant autoantigens or tolerogenic function. This is not a trivial oversight, as dendritic cells link events occurring in the mucosa and adaptive autoimmunity.

Hypoxia, VEGF, inflammatory growth factors and chemokines are responsible for synovial angiogenesis. Triptolide inhibits an angiogenic cascade in experimental RA58 and the other agents, artesunate, curcumin and tanshinone IIA have been associated with reduced HIF-1α/VEGF signaling. Anti-angiogenic activity may be beneficial in preventing access by leukocytes and preventing the formation of the pannus, however chronic suppression of the vascular system may have adverse effects on repair. Perfusion, endothelial phenotype and tissue oxygenation should therefore be measured in studies and the presence of angiogenesis inferred from the amount of VEGF expression.

Oxidative Stress, Mitochondrial Quality Control, Autophagy, Pyroptosis, and Ferroptosis

Pyroptosis and NLRP3–caspase-1 signaling provide a plausible link among ROS, myeloid activation, and IL-1-family cytokines. Celastrol and icariin studies report changes in this pathway,52,57 but causal attribution requires target engagement and perturbation. Ferroptosis evidence is weaker: marker changes in lipid peroxidation, GPX4, or system Xc− are not sufficient without rescue by canonical ferroptosis inhibitors, iron dependence, and exclusion of apoptosis or necroptosis.69,75,76 Accordingly, ferroptosis is treated as an emerging hypothesis rather than an established anti-RA mechanism.

Autophagy may have protective effects by eliminating damaged organelles, and may also promote the survival of pathogenic FLSs. Berberine has been related to the autophagy-related regulation of IL-21 signaling and Th17/Treg balance, while icariin and other flavonoids have been related to PI3K-AKT-mTOR-ULK1 pathways. LC3-II is not enough on its own to interpret – accumulation of LC3-II can be due to the increase of autophagosomes, or autophagosomes may not be degraded. A combination of tandem reporters, lysosomal inhibitors, and genetic perturbation are essential.77

Pyroptosis and NLRP3-caspase-1 signaling provide a plausible link among ROS, macrophage activation, and IL-1 family cytokines. Celastrol has direct preclinical evidence in this domain,52 while icariin and other compounds have been reported to reduce NLRP3 activation.57 Ferroptosis has more recently been implicated in FLS and chondrocyte injury, and icariin has been reported to modulate ferroptosis-related markers.69 Yet much of the ferroptosis literature is marker-based. A rigorous claim requires rescue by canonical inhibitors, dependence on GPX4 or system Xc−, demonstration of iron-dependent lipid peroxidation, and exclusion of apoptosis or necroptosis.75,76

Gut-Joint Axis and Systemic Immunometabolism

The gut microbiota can impact on RA via barrier integrity, microbial metabolites, molecular mimicry and modulation of T-cell and myeloid programs. One of the most convincing of these compounds studied was berberine, which was shown to have low systemic exposure, high exposure in the gut, and effects on gut cortistatin and the gut microbial community in a coherent pharmacological model.53 Other constituents, such as curcumin, ginsenosides and polysaccharide derived products might also have the ability to alter the microbial communities or the metabolism of bile acids and short-chain-fatty-acids.78,79

Animal facility, diet, antibiotics, sequencing pipeline, DMARD exposure and geography are significant sources of microbiome findings confounding. Changing the relative abundance of the microbiota is not sufficient to prove causality-further fecal-transfer and/or gnotobiotic experiments, combined with metabolite rescue and host loss-of-function experiments are needed to demonstrate that microbiota changes underlie efficacy.

Convergent Signaling Networks: Useful Map, Insufficient Proof

Seven recurrent signaling modules appear across the literature: NF-κB/MAPK, JAK/STAT, PI3K–AKT–mTOR, ROS–Nrf2, NLRP3–caspase-1, RANKL–NFATc1, and HIF-1α–VEGF. These modules are useful for organizing biological readouts, but they do not form a linear causal chain and should not be counted as separate direct targets simply because multiple downstream proteins change after treatment. Figure 1 summarizes the principal compartments and signaling nodes while explicitly separating proposed directionality from causal certainty. Table 1 labels evidence as associative unless proximal target engagement, necessity, or rescue has been demonstrated.

Upstream shift of mechanistic studies. Chemoproteomics can be used for electrophilic compounds, like celastrol and andrographolide; Thermal proteome profiling and cellular target engagement can be used to identify targets that are non-covalent; CRISPR perturbation can be used to test necessity; and rescue with constitutively active proteins and with drug resistant proteins can be used to test pathway dependence. Target modulation should then be investigated using pharmacokinetic-pharmacodynamic modelling to determine whether or not clinically plausible exposure allows for target modulation. In the absence of this sequence, “multi-target” may lose its meaning and become a term to describe poor definition of target rather than a true therapeutic benefit.80

Clinical Evidence, Product Identity, Pharmacokinetics, Safety, and Delivery

Clinical Products are Not Interchangeable with Isolated Molecules

The strongest human evidence in this field concerns standardized T. wilfordii Hook F (TwHF) preparations rather than purified triptolide or celastrol. In the multicentre TRIFRA trial, 207 patients with active RA were randomized to MTX 12.5 mg weekly, TwHF 20 mg three times daily, or the combination for 24 weeks; ACR50 responses were 46.4%, 55.1%, and 76.8%, respectively.15 These data establish clinical activity of the standardized botanical intervention but cannot be attributed to a single constituent. The 2023 International Consensus Guidance, based on 19 randomized trials involving 1795 participants, similarly evaluates TwHF as a product and emphasizes reproductive, hepatic, and renal safety considerations.16 Therefore, standardized TwHF extract/glycosides, purified triptolide, and purified celastrol are treated as distinct interventions throughout this review.81,82

The same product–constituent rule applies to sinomenine and paeoniflorin. Marketed sinomenine hydrochloride preparations and total glucosides of peony are formulated products with clinical use in China; their efficacy or safety should not be assigned automatically to sinomenine base or paeoniflorin alone. Curcumin provides a second major example of formulation dependence: clinical studies have used chemically and pharmacokinetically different preparations, including conventional curcumin, nanomicelles, and bioavailability-enhanced matrices. A 36-patient double-blind trial tested 250 or 500 mg twice daily for 90 days, whereas other studies used different formulations and doses.19–23,83 These trials are signals of formulation-specific adjunctive activity, not evidence for a single interchangeable entity called “curcumin”. Table 2 summarizes these translational distinctions. Small clinical studies have also examined resveratrol and quercetin in RA, but these findings remain intervention-specific and do not establish efficacy for other isolated constituents.84,85

Human studies remain much thinner than the preclinical literature and should be interpreted using conventional clinical-trial criteria: randomization and blinding, sample size, comparator, background DMARD therapy, formulation identity, duration, validated disease-activity outcomes, structural/imaging endpoints, and adverse events. Small adjunctive studies can justify larger trials but are not comparable in evidential weight to the TwHF extract trials and do not support replacement of MTX, bDMARDs, or tsDMARDs. Structural protection and combination safety remain unproven for nearly all isolated compounds.

Exposure, Metabolism, Formulation, and PK/PD

Exposure–response mismatch is a central translational problem. Curcumin shows low and highly formulation-dependent systemic exposure, with conjugated metabolites often dominating over free parent compound.24–27 Berberine undergoes extensive intestinal first-pass elimination and has low plasma parent-drug levels despite high gastrointestinal exposure.28 Ginsenosides can be converted by the microbiota to metabolites such as compound K, while paeoniflorin and icariin also undergo extensive biotransformation. Consequently, a 20–100 μM parent-compound cell experiment may be mechanistically informative but clinically irrelevant if free parent drug at that concentration is not achievable at the target tissue. Table 2 therefore separates nominal administered dose from the more important question of systemic or tissue exposure.

Translational pharmacology should measure the free parent compound and major metabolites in plasma, synovial fluid, and synovial tissue; establish temporal correlation between the exposure and modulation of the target(s); and assess free active molecular species in human cells. Nanoparticles, liposomes, phospholipid complexes, hydrogels, and joint targeted delivery are ways to increase exposure, but these raise a new medicinal product, for which efficacy and toxicity are not known from the parent herb. Delivery systems should be compared to exposure matched free compound and tested for carrier related immunogenicity or accumulation.

Standardization of botanicals is also crucial. Efficacy and Toxicity are subject to change depending on species authentication, plant part used for cultivation, extraction solvent, marker compounds, impurity profiles and batch-to-batch variability. Removal or control of toxic constituents is of prime importance for T. wilfordii products. Only reporting mass of “extract” will not allow for reproducibility or mechanistic attributions.

Safety and Drug–Drug Interactions

Natural origin does not imply a favorable therapeutic index. TwHF products, triptolide, and celastrol raise concerns involving reproductive, hepatic, renal, hematologic, gastrointestinal, and immune toxicity; reproductive risk is specifically emphasized in the international TwHF guidance.16,86 Emodin and related anthraquinones require gastrointestinal and hepatic caution, while multiple alkaloids, flavonoids, and botanical constituents can affect metabolic enzymes or transporters. For chronic RA treatment, the clinically relevant question is not whether an agent suppresses inflammation at a tolerated experimental dose, but whether efficacy is separated from toxicity across repeated exposure and in combination with standard DMARDs.87,88

Combination studies should consider the pharmacokinetic and pharmacodynamic interactions with methotrexate, glucocorticoids, biologics and JAK inhibitors. Prospective monitoring of hepatic enzymes, blood counts, renal function, reproductive toxicity, QT effects (where applicable) and infection endpoints should be considered. Clinical attractiveness does not only depend on the ability of a compound to reduce the dose of a classical drug in an animal model, but also on the ability to enhance the benefit-risk ratio for the combination.

Methodological Limitations and Recurrent Failure Modes

Firstly, many studies involve giving a preventative dose before or at the same time as the arthritis is induced. This design is an interference design aimed at testing interference with model initiation NOT treatment of established RA. Objective arthritis should be reached before beginning therapeutic dosing and methotrexate or another suitable positive control should be used as a benchmark.

Secondly, animal models contain only part of the picture of RA. CIA is incredibly useful for Adaptive Immunity and erosive disease but requires collagen immunization, while AIA is extremely innate and adjuvant driven and serum transfer models do not require adaptive priming. Model replication can identify if a compound is working upstream on the tolerance or downstream on the effecter inflammation or is working generally through toxicity.

Thirdly, doses are sometimes not related to pharmacokinetics. There is broad suppression and suppression in pathways is sometimes under-controlled in high concentrations. Only administered dose should be reported in studies, purity, solubility, free concentration, stability, cytotoxicity, and human equivalent exposure should be reported.

Fourthly, pathway inference is often circular. Phosphorylated p65 decreases and NF-κB is identified as the mechanism in a compound that yields reduction of arthritis. This does not rule out the possibility that decreased tissue damage secondarily results in decreased NF-κB. Experiments of necessity and sufficiency are necessary. This is equally true of JAK-STAT, PI3K-AKT-mTOR, Nrf2, NLRP3 and ferroptosis claims.

Fifth, publication and selection bias could be causing an overestimate of consistency. Less noticeable are the negative compounds, failed programs of replication, and toxicity restricted programs. Most studies are single center, involve a single sex and are inadequate in pre-registering endpoints and reporting on randomization and blinding. Such limitations should be taken into consideration before attempting to quantitatively rank compounds or pathways.

Future Directions

Substantive progress requires a shift from broad anti-inflammatory description to causal, exposure-aware immunology. The following priorities would materially strengthen the field:

  • Use primary human RA synovial tissue, matched blood, synovial organoids, explants, and multicellular co-cultures to test whether compounds reprogram disease-relevant macrophage and fibroblast states rather than merely suppress acute cytokine responses.

  • Integrate single-cell RNA sequencing, spatial transcriptomics, imaging mass cytometry, and proteomics with orthogonal functional assays. Molecular signatures should be linked to cell abundance, localization, migration, efferocytosis, matrix invasion, and osteoclast resorption.

  • Establish proximal targets using chemoproteomics, target-engagement assays, CRISPR perturbation, and rescue experiments. Multi-target activity should be demonstrated, not assumed from downstream pathway breadth.

  • Match in vitro concentrations to unbound human exposure and test major circulating or microbiota-derived metabolites. Joint tissue distribution and PK/PD relationships should be measured directly.

  • Evaluate established disease, both sexes, aged animals, relevant comorbidities, and combination therapy with methotrexate or biologics. Structural outcomes and infection/toxicity endpoints should accompany arthritis scores.

  • Standardize botanical taxonomy, extraction, chemical fingerprints, active-constituent ranges, impurities, and stability. Isolated compounds and standardized extracts should be developed as distinct products.

  • Design biomarker-stratified Phase I/II trials with transparent randomization, allocation concealment, validated clinical outcomes, and pre-specified safety monitoring. Myeloid-, lymphoid-, and fibroblast-dominant synovial pathotypes may provide rational enrichment strategies.

  • Treat prevention as a separate research question. Studies in ACPA-positive at-risk individuals would require exceptionally strong safety data and evidence that an intervention changes immune maturation rather than only inflammatory symptoms.

Discussion

The evidence synthesis supports three conclusions. First, the literature contains reproducible biological activity across macrophage, RA-FLS, osteoclast, T-cell, neutrophil, endothelial, and metabolic compartments, but downstream pathway breadth is common and therefore has low discriminative value by itself. Second, translational credibility rises sharply when chemical identity, clinically plausible exposure, and causal target engagement are aligned; this is still uncommon for isolated TCM-derived constituents. Third, product identity matters: standardized TwHF extracts/glycosides, sinomenine hydrochloride preparations, total glucosides of peony, purified constituents, metabolites, and formulation-enhanced products are different interventions and should not share efficacy claims by association.

This framework also clarifies why an extensive preclinical literature has produced relatively few clinically mature interventions. Preventive dosing in inducible arthritis models, high nominal in vitro concentrations, pathway readouts measured after non-specific cytotoxicity, and lack of rescue or target-engagement experiments can all generate apparently coherent mechanistic narratives without establishing a clinically actionable mechanism. The problem is not that multi-compartment pharmacology is implausible; rather, it remains difficult to distinguish therapeutically useful polypharmacology from chemically driven promiscuity or downstream stress-response suppression.

Among current translational paths, standardized TwHF is the best-supported clinically studied botanical product, although safety and reproductive risk limit generalization. Berberine provides a distinct, exposure-consistent strategy in which gut-restricted or microbiota-mediated action may be more plausible than direct synovial exposure. Selected RA-FLS/osteoclast-directed leads may also be worth developing if structural benefit, target engagement, and a chronic therapeutic window can be shown. In contrast, high-micromolar parent-compound cell studies without corresponding human exposure represent the weakest translational evidence. These distinctions are more informative than ranking compounds by the number of pathways they are reported to alter.

Accordingly, the next generation of studies should be designed around a product-specific chain of evidence: verified chemistry → unbound exposure at the relevant compartment → proximal target engagement → causal perturbation/rescue → disease-relevant cellular and structural outcomes → combination safety against treat-to-target background therapy. Applying this sequence would allow the field to identify which TCM-derived interventions are credible adjuncts or drug-development leads and which remain primarily pharmacological hypotheses.

Conclusion

TCM-derived bioactive constituents provide useful pharmacological leads for RA, but their evidence hierarchy is highly uneven. The strongest translational path is standardized TwHF as a clinically studied botanical product; a second plausible path is exposure-consistent, gut-restricted berberine pharmacology; and a third is the development of selected RA-FLS/osteoclast-directed molecules with demonstrable target engagement and structural benefit. The weakest evidence consists of high-μM parent-compound cell studies that lack human exposure matching, proximal target validation, or rescue experiments. For most isolated compounds, structural protection, long-term combination safety, and clinically relevant PK/PD remain unproven. Future work should prioritize four operational requirements: chemically defined interventions, exposure-matched pharmacology, causal target validation in human RA-relevant systems, and adequately powered add-on trials with structural and safety endpoints. Until those requirements are met, TCM-derived compounds should be regarded as mechanistic leads or potential adjuncts rather than replacements for guideline-directed DMARD therapy.

Funding Statement

This work was supported by the National Natural Science Foundation of China (Nos. 82374491 and 82160911); the Gansu Provincial Health Commission Scientific Research Management Project (GSWSKY2023-642024); the In-house Top Talent Program of the Affiliated Hospital of Gansu University of Traditional Chinese Medicine; the National Construction Project for TCM Specialties with Distinctive Advantages—Orthopedics and Traumatology (Rehabilitation Orthopedics) (Gan Zhong Yi Yao Yi Zheng Han [2026] No. 1); the 2025 Clinical Key Specialty Capability Enhancement Project (Geriatric Orthopedics); and the National Traditional Chinese Medicine Advantage Specialty (Orthopedics).

Data Sharing Statement

No original datasets were generated for this review. All information analyzed is available in the cited literature.

Author Contributions

Hui Li: Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing. Xingwen Xie: Conceptualization, Methodology, Supervision, Funding acquisition, Writing – original draft, Writing – review & editing. Ning Li: Conceptualization, Methodology, Supervision, Funding acquisition, Writing – original draft, Writing – review & editing. All authors approved the final manuscript and agree to be accountable for the work. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors declare no commercial or financial relationships that could be construed as a potential conflict of interest and confirm that they have no product-related consultancy, patent, or licensing interests involving TwHF, sinomenine, or related preparations.

References

  • 1.Black RJ, Cross M, Haile LM, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e594–17. doi: 10.1016/S2665-9913(23)00211-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038. doi: 10.1016/S0140-6736(16)30173-8 [DOI] [PubMed] [Google Scholar]
  • 3.Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46:183–196. doi: 10.1016/j.immuni.2017.02.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–2219. doi: 10.1056/NEJMra1004965 [DOI] [PubMed] [Google Scholar]
  • 5.van der Woude D, van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32:174–187. doi: 10.1016/j.berh.2018.10.005 [DOI] [PubMed] [Google Scholar]
  • 6.D’Orazio A, Cirillo AL, Greco G, et al. Pathogenesis of rheumatoid arthritis: one year in review 2024. Clin Exp Rheumatol. 2024. PMID: 39315569. doi: 10.55563/clinexprheumatol/0307ed [DOI] [PubMed] [Google Scholar]
  • 7.Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–2581. doi: 10.1002/art.27584 [DOI] [PubMed] [Google Scholar]
  • 8.Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi: 10.1038/nrdp.2018.1 [DOI] [PubMed] [Google Scholar]
  • 9.Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73:924–939. doi: 10.1002/acr.24596 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3–18. doi: 10.1136/ard-2022-223356 [DOI] [PubMed] [Google Scholar]
  • 11.Kour G, Haq SA, Bajaj BK, Gupta PN, Ahmed Z. Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: in vitro and in vivo bases, clinical evidence and future trends. Pharmacol Res. 2021;169:105618. doi: 10.1016/j.phrs.2021.105618 [DOI] [PubMed] [Google Scholar]
  • 12.Liu X, Wang Z, Qian H, et al. Natural medicines of targeted rheumatoid arthritis and its action mechanisms. Front Immunol. 2022;13:945129. doi: 10.3389/fimmu.2022.945129 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kciuk M, Garg A, Rohilla M, et al. Therapeutic potential of plant-derived compounds and plant extracts in rheumatoid arthritis—comprehensive review. Antioxidants. 2024;13(7):775. doi: 10.3390/antiox13070775 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kalita JK, Singh NA, Biswas S, Nath B, Chakraborty R, Sen S. Phytochemicals in arthritis management: insight into pharmacodynamic potency with pharmacokinetic profile. Inflammopharmacology. 2026;34(5):3029–3054. doi: 10.1007/s10787-026-02194-6 [DOI] [PubMed] [Google Scholar]
  • 15.Lv QW, Zhang W, Shi Q, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis. 2015;74:1078–1086. doi: 10.1136/annrheumdis-2013-204807 [DOI] [PubMed] [Google Scholar]
  • 16.Zhang X, Xia J, Jiang Y, et al. 2023 International Consensus Guidance for the use of Tripterygium wilfordii Hook F in the treatment of active rheumatoid arthritis. J Autoimmun. 2024;142:103148. doi: 10.1016/j.jaut.2023.103148 [DOI] [PubMed] [Google Scholar]
  • 17.Liu W, Zhang Y, Zhu W, et al. Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte/macrophage subsets. Front Immunol. 2018;9:2228. doi: 10.3389/fimmu.2018.02228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Liu W, Qian X, Ji W, Lu Y, Wei G, Wang Y. Effects and safety of Sinomenine in treatment of rheumatoid arthritis contrast to methotrexate: a systematic review and meta-analysis. J Tradit Chin Med. 2016;36:564–577. doi: 10.1016/S0254-6272(16)30075-9 [DOI] [PubMed] [Google Scholar]
  • 19.Amalraj A, Varma K, Jacob J, et al. A novel highly bioavailable curcumin formulation improves symptoms and diagnostic indicators in rheumatoid arthritis patients: a randomized, double-blind, placebo-controlled, two-dose, three-arm, and parallel-group study. J Med Food. 2017;20:1022–1030. doi: 10.1089/jmf.2017.3930 [DOI] [PubMed] [Google Scholar]
  • 20.Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26:1719–1725. doi: 10.1002/ptr.4639 [DOI] [PubMed] [Google Scholar]
  • 21.Javadi M, Khadem Haghighian H, Goodarzy S, Abbasi M, Nassiri-Asl M. Effect of curcumin nanomicelle on the clinical symptoms of patients with rheumatoid arthritis: a randomized, double-blind, controlled trial. Int J Rheum Dis. 2019;22:1857–1862. doi: 10.1111/1756-185X.13688 [DOI] [PubMed] [Google Scholar]
  • 22.Pourhabibi-Zarandi F, Rafraf M, Zayeni H, Asghari-Jafarabadi M, Ebrahimi AA. Effects of curcumin supplementation on metabolic parameters, inflammatory factors and obesity values in women with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2022;36:1797–1806. doi: 10.1002/ptr.7422 [DOI] [PubMed] [Google Scholar]
  • 23.Bhat SS, Ahmed S, Reji R, et al. Efficacy and safety of curcumin in maintaining remission during disease-modifying antirheumatic drug withdrawal in rheumatoid arthritis at 52 weeks: a Phase III double-blind, randomized placebo-controlled trial. Rheumatol Int. 2023;43:2193–2200. doi: 10.1007/s00296-023-05417-z [DOI] [PubMed] [Google Scholar]
  • 24.Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60:1620–1637. doi: 10.1021/acs.jmedchem.6b00975 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807–818. doi: 10.1021/mp700113r [DOI] [PubMed] [Google Scholar]
  • 26.Fança-Berthon P, Tenon M, Le Bouter-Banon S, et al. Pharmacokinetics of a single dose of turmeric curcuminoids depends on formulation: results of a human crossover study. J Nutr. 2021;151:1802–1816. doi: 10.1093/jn/nxab087 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Thanawala S, Shah R, Doyle L, Upadhyay V. Comparative pharmacokinetics of curcuminoids from water-dispersible turmeric extract against a curcuminoids-piperine combination: an open-label, randomized, balanced, 2-treatment, 2-sequence, 2-period crossover study. Altern Ther Health Med. 2024;30:18–23. [PubMed] [Google Scholar]
  • 28.Liu YT, Hao HP, Xie HG, et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010;38:1779–1784. doi: 10.1124/dmd.110.033936 [DOI] [PubMed] [Google Scholar]
  • 29.Malmström V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2017;17:60–75. doi: 10.1038/nri.2016.124 [DOI] [PubMed] [Google Scholar]
  • 30.Catrina AI, Svensson CI, Malmström V, Schett G, Klareskog L. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol. 2017;13:79–86. doi: 10.1038/nrrheum.2016.200 [DOI] [PubMed] [Google Scholar]
  • 31.Nielen MMJ, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380–386. doi: 10.1002/art.20018 [DOI] [PubMed] [Google Scholar]
  • 32.Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122:1791–1802. doi: 10.1172/JCI60975 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Krishnamurthy A, Joshua V, Haj Hensvold A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016;75:721–729. doi: 10.1136/annrheumdis-2015-208093 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;5:178ra40. doi: 10.1126/scitranslmed.3005580 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Alivernini S, MacDonald L, Elmesmari A, et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat Med. 2020;26:1295–1306. doi: 10.1038/s41591-020-0939-8 [DOI] [PubMed] [Google Scholar]
  • 36.Zhang F, Wei K, Slowikowski K, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019;20:928–942. doi: 10.1038/s41590-019-0378-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Stephenson W, Donlin LT, Butler A, et al. Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation. Nat Commun. 2018;9:791. doi: 10.1038/s41467-017-02659-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Culemann S, Grüneboom A, Nicolás-ávila JÁ, et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature. 2019;572:670–675. doi: 10.1038/s41586-019-1471-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Orange DE, Agius P, DiCarlo EF, et al. Identification of three rheumatoid arthritis disease subtypes by machine learning integration of synovial histologic features and RNA sequencing data. Arthritis Rheumatol. 2018;70:690–701. doi: 10.1002/art.40428 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Ouboussad L, Burska AN, Melville A, Buch MH. Synovial tissue heterogeneity in rheumatoid arthritis and changes with biologic and targeted synthetic therapies to inform stratified therapy. Front Med. 2019;6:45. doi: 10.3389/fmed.2019.00045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mantel I, Fein MR, Donlin LT. Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets. Curr Opin Rheumatol. 2023;35:249–254. doi: 10.1097/BOR.0000000000000940 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Kuo D, Ding J, Cohn IS, et al. HBEGF+ macrophages in rheumatoid arthritis induce fibroblast invasiveness. Sci Transl Med. 2019;11:eaau8587. doi: 10.1126/scitranslmed.aau8587 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Croft AP, Campos J, Jansen K, et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature. 2019;570:246–251. doi: 10.1038/s41586-019-1263-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Mizoguchi F, Slowikowski K, Wei K, et al. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun. 2018;9:789. doi: 10.1038/s41467-018-02892-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Rao DA, Gurish MF, Marshall JL, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110–114. doi: 10.1038/nature20810 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8:656–664. doi: 10.1038/nrrheum.2012.153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021;22:10922. doi: 10.3390/ijms222010922 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Weyand CM, Goronzy JJ, Cheng Q. Immunometabolism in rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:291–306. doi: 10.1038/s41584-021-00601-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Fearon U, Canavan M, Biniecka M, Veale DJ. Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat Rev Rheumatol. 2016;12:385–397. doi: 10.1038/nrrheum.2016.69 [DOI] [PubMed] [Google Scholar]
  • 50.Yao RB, Zhao ZM, Zhao LJ, Cai H. Sinomenine inhibits the inflammatory responses of human fibroblast-like synoviocytes via the TLR4/MyD88/NF-κB signaling pathway in rheumatoid arthritis. Pharmazie. 2017;72:355–360. doi: 10.1691/ph.2017.6946 [DOI] [PubMed] [Google Scholar]
  • 51.Jiang H, Fan D, Zhou G, et al. Sinomenine ameliorates adjuvant-induced arthritis by inhibiting neutrophil extracellular trap formation. Sci Rep. 2023;13:3049. doi: 10.1038/s41598-023-30922-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Jing M, Yang J, Zhang L, et al. Celastrol inhibits rheumatoid arthritis through the ROS-NF-κB-NLRP3 inflammasome axis. Int Immunopharmacol. 2021;98:107879. doi: 10.1016/j.intimp.2021.107879 [DOI] [PubMed] [Google Scholar]
  • 53.Yue M, Xia Y, Shi C, et al. Berberine ameliorates collagen-induced arthritis in rats by suppressing Th17 cell responses via inducing cortistatin in the gut. FEBS J. 2017;284:2786–2801. doi: 10.1111/febs.14147 [DOI] [PubMed] [Google Scholar]
  • 54.Dinesh P, Rasool M. Berberine mitigates IL-21/IL-21R mediated autophagic influx in fibroblast-like synoviocytes and regulates Th17/Treg imbalance in rheumatoid arthritis. Apoptosis. 2019;24:644–661. doi: 10.1007/s10495-019-01548-6 [DOI] [PubMed] [Google Scholar]
  • 55.Zhang L, Zhu M, Li M, et al. Ginsenoside Rg1 attenuates adjuvant-induced arthritis in rats via modulation of the PPAR-γ/NF-κB signal pathway. Oncotarget. 2017;8:55384–55393. doi: 10.18632/oncotarget.19526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Zheng Y, Wei K, Jiang P, et al. Macrophage polarization in rheumatoid arthritis: signaling pathways, metabolic reprogramming, and crosstalk with synovial fibroblasts. Front Immunol. 2024;15:1394108. doi: 10.3389/fimmu.2024.1394108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Wu ZM, Luo J, Shi XD, Zhang SX, Zhu XB, Guo J. Icariin alleviates rheumatoid arthritis via regulating miR-223-3p/NLRP3 signalling axis. Autoimmunity. 2020;53:450–458. doi: 10.1080/08916934.2020.1836488 [DOI] [PubMed] [Google Scholar]
  • 58.Kong X, Zhang Y, Liu C, et al. Anti-angiogenic effect of triptolide in rheumatoid arthritis by targeting angiogenic cascade. PLoS One. 2013;8:e77513. doi: 10.1371/journal.pone.0077513 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Su X, Guo W, Yuan B, et al. Artesunate attenuates bone erosion in rheumatoid arthritis by suppressing osteoclastogenesis through p62/Nrf2 signaling. Biomed Pharmacother. 2021;137:111382. doi: 10.1016/j.biopha.2021.111382 [DOI] [PubMed] [Google Scholar]
  • 60.Xu H, He Y, Yang X, et al. Anti-malarial agent artesunate inhibits TNF-α-induced production of proinflammatory cytokines via inhibition of NF-κB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology. 2007;46:920–926. doi: 10.1093/rheumatology/kem014 [DOI] [PubMed] [Google Scholar]
  • 61.Li X, Qin Y-H, Du P-Q, et al. Andrographolide inhibits migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes via the HIF-1α signaling pathway. Life Sci. 2015;136:67–72. doi: 10.1016/j.lfs.2015.06.019 [DOI] [PubMed] [Google Scholar]
  • 62.Zhang X, Guan X, Piao Y, Che X, Si M, Jin J. Baicalein induces apoptosis of rheumatoid arthritis synovial fibroblasts through inactivation of the PI3K/Akt/mTOR pathway. Evid Based Complement Alternat Med. 2022;2022:3643265. doi: 10.1155/2022/3643265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Li G, Du H, Huang Q, et al. Tanshinone IIA Induces Apoptosis in Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via Blockade of the Cell Cycle in the G2/M Phase and a Mitochondrial Pathway. Biol Pharm Bull. 2014;37:1366–1372. doi: 10.1248/bpb.b14-00301 [DOI] [PubMed] [Google Scholar]
  • 64.Jia Z, He J. Paeoniflorin ameliorates rheumatoid arthritis in rat models through oxidative stress, inflammation and cyclooxygenase 2. Exp Ther Med. 2016;11:655–659. doi: 10.3892/etm.2015.2908 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Yang J, Wei Z, Li H, et al. Paeoniflorin inhibits the inflammation of rheumatoid arthritis fibroblast-like synoviocytes by downregulating hsa_circ_009012. Heliyon. 2024;10:e30555. doi: 10.1016/j.heliyon.2024.e30555 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Kim HR, Kim BM, Won JY, et al. Quercetin, a plant polyphenol, has potential for the prevention of bone destruction in rheumatoid arthritis. J Med Food. 2019;22:152–161. doi: 10.1089/jmf.2018.4259 [DOI] [PubMed] [Google Scholar]
  • 67.Wei Z, Lv Q, Xia Y, et al. Norisoboldine, an anti-arthritis alkaloid isolated from Radix Linderae, attenuates osteoclast differentiation and bone erosion in collagen-induced arthritis. Int Immunopharmacol. 2015;11:1113. PMID: 26221077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Peng Q, Wang J, Han M, et al. Tanshinone IIA inhibits osteoclastogenesis and bone destruction in rheumatoid arthritis through an LDHC-ROS-dependent mechanism. Chin Med. 2023;18:54. doi: 10.1186/s13020-023-00765-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Luo H, Zhang R. Icariin enhances cell survival in lipopolysaccharide-induced synoviocytes by suppressing ferroptosis via the Xc−/GPX4 axis. Exp Ther Med. 2021;21:72. doi: 10.3892/etm.2020.9504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Chen S, Xue W, Wu Z, et al. Quercetin, a compound of the total flavonoids of Periploca forrestii Schltr. ameliorates rheumatoid arthritis by targeting TNF-α. J Inflamm Res. 2025;18:2879–2898. doi: 10.2147/JIR.S497166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Huang G, Yuan K, Zhu Q, et al. Triptolide inhibits the inflammatory activities of neutrophils to ameliorate chronic arthritis. Mol Immunol. 2018;101:210–220. doi: 10.1016/j.molimm.2018.06.012 [DOI] [PubMed] [Google Scholar]
  • 72.Zhu M, Yuan K, Lu Q, et al. Emodin promotes neutrophil apoptosis and suppresses neutrophil extracellular trap formation in inflammatory arthritis. Mol Immunol. 2019;112:188–197. doi: 10.1016/j.molimm.2019.05.010 [DOI] [PubMed] [Google Scholar]
  • 73.Schneider AH, Taira TM, Públio GA, et al. Neutrophil extracellular traps mediate bone erosion in rheumatoid arthritis by enhancing RANKL-induced osteoclastogenesis. Br J Pharmacol. 2024;181:429–446. doi: 10.1111/bph.16227 [DOI] [PubMed] [Google Scholar]
  • 74.Carmona-Rivera C, Carlucci PM, Moore E, et al. Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. Sci Immunol. 2017;2:eaag3358. doi: 10.1126/sciimmunol.aag3358 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–1072. doi: 10.1016/j.cell.2012.03.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273–285. doi: 10.1016/j.cell.2017.09.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 2021;17:1–382. doi: 10.1080/15548627.2020.1797280 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Li B, Liu J, He C, Deng Z, Zhou X, Peng R. Unveiling the therapeutic potential of berberine in rheumatoid arthritis: a comprehensive study of network pharmacology, metabolomics, and intestinal flora. J Inflamm Res. 2024;17:10849–10869. doi: 10.2147/JIR.S493892 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Zaiss MM, Joyce Wu HJ, Mauro D, Schett G, Ciccia F. The gut-joint axis in rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:224–237. doi: 10.1038/s41584-021-00585-3 [DOI] [PubMed] [Google Scholar]
  • 80.Jafari R, Almqvist H, Axelsson H, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9:2100–2122. doi: 10.1038/nprot.2014.138 [DOI] [PubMed] [Google Scholar]
  • 81.Zhou YY, Xia X, Peng WK, et al. The effectiveness and safety of Tripterygium wilfordii Hook. F extracts in rheumatoid arthritis: a systematic review and meta-analysis. Front Pharmacol. 2018;9:356. doi: 10.3389/fphar.2018.00356 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med. 2009;151:229–240, W49–W51. doi: 10.7326/0003-4819-151-4-200908180-00005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Kou H, Huang L, Jin M, He Q, Zhang R, Ma J. Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis. Front Immunol. 2023;14:1121655. doi: 10.3389/fimmu.2023.1121655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Khojah HM, Ahmed S, Abdel-Rahman MS, Elhakeim EH. Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study. Clin Rheumatol. 2018;37:2035–2042. doi: 10.1007/s10067-018-4080-8 [DOI] [PubMed] [Google Scholar]
  • 85.Javadi F, Eghtesadi S, Ahmadzadeh A, et al. The effect of quercetin on plasma oxidative status, C-reactive protein and blood pressure in women with rheumatoid arthritis. Int J Prev Med. 2014;5:293–301. [PMC free article] [PubMed] [Google Scholar]
  • 86.Zhang C, Sun PP, Guo HT, et al. Safety profiles of Tripterygium wilfordii Hook F: a systematic review and meta-analysis. Front Pharmacol. 2016;7:402. doi: 10.3389/fphar.2016.00402 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258–265. doi: 10.1016/S0140-6736(14)61704-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529–535. doi: 10.1136/annrheumdis-2013-204575 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No original datasets were generated for this review. All information analyzed is available in the cited literature.


Articles from Journal of Inflammation Research are provided here courtesy of Dove Press

RESOURCES